Field Safety Corrective Actions and Field Safety Notices in South Africa

1. Key takeaways

A Field Safety Corrective Action (FSCA) is an action taken by a manufacturer to reduce the risk of death or serious deterioration in health associated with the use of a medical device, and such an action must be communicated to device users through a Field Safety Notice (FSN). SAHPRA provides guidance on the content of the initial FSCA report and on the methods of delivering the FSN in its FAQs on Medical Device Adverse Events and FSCA. FSCA reporting and adverse event reporting are two parallel obligations — a single event can trigger both at the same time. The practical consequence is that manufacturers cannot treat a field safety action as a substitute for a vigilance report, nor the other way around; the two workstreams must run side by side, share a common factual record, and each be documented to the standard that SAHPRA expects when it later reviews the case.

2. Legal basis

3. Expert insights

Insight one: the trigger for an FSCA is an unacceptable increase in risk, not harm that has already occurred. SAHPRA makes clear that an FSCA may be prompted by one or more adverse events, or by incidents involving devices already distributed, whenever they constitute an unacceptable increase in risk during use. This means the FSCA is a preventive tool — the manufacturer does not need to wait until injury has actually happened. A worsening trend in complaints or a design flaw discovered in testing can already be sufficient grounds for action.

Insight two: the content checklist for the initial report is specific, and it requires an explanation of why other batches are not affected. The official requirements state that the initial report must include at least the manufacturer name, product name, product code and batch numbers; where the FSCA concerns only specific batches, an explanation of why other batches or batch groups are not affected; a list of all countries affected; and background information and the rationale for initiating the action. The second item is a distinctly South African requirement, and companies should prepare a differentiated batch analysis well in advance rather than assembling it under deadline pressure.

Insight three: the background information must include the relevant elements of the risk analysis and the justification for the corrective and preventive actions. The official requirements cover: a description of the device defect, fault or malfunction; an explanation of the potential hazards associated with continued use; the relevant risks to patients, users or any other person; the risks that prior use may already have posed to patients; the relevant elements of the risk analysis; and the description and justification of the corrective and preventive action(s). In substance, this sequence imports the outputs of the risk management file directly into the FSCA report, so a well-maintained risk management file is the fastest route to a compliant report.

Insight four: the FSN must give users actions they can actually execute. The officially suggested FSN content includes: identifying and quarantining the device; the method of retrieval, disposal or modification; recommended patient follow-up; and a request to forward the FSN to all organisations and individuals who need to be aware of it. An FSN is not a press release; it is an operational instruction — its clarity directly determines how effectively the risk is controlled in the field.

Insight five: the method of delivery must be provable. The officially listed delivery channels include e-mail or registered mail, fax, personal visits and telephone contact. The choice of channel is not the decisive point; whether delivery can be proven is — companies should retain delivery records, such as mail receipts, registered-mail confirmations, visit logs and call notes, to demonstrate that the FSN actually reached the users.

4. Practical recommendations

1. Define FSCA decision criteria: use an unacceptable increase in risk during use as the trigger line, and document every assessment.
2. Prepare an FSCA initial report template in advance: populate it item by item against the official checklist.
3. Perform the differentiated batch analysis early: be ready to answer why other batches are not affected.
4. Write the FSN as an operational instruction: quarantine, retrieval, disposal, patient follow-up and forwarding requirements.
5. Retain delivery evidence: e-mail receipts, registered-mail confirmations, visit and call records.
6. Process FSCA and adverse event reporting in parallel: neither substitutes for the other.

5. Verification checklist

• □ FSCA trigger criteria have been established (unacceptable increase in risk)
• □ The initial report template has been pre-built against the official checklist (8 categories of elements)
• □ The differentiated batch analysis has been completed (explaining why other batches are not affected)
• □ The list of affected countries has been prepared
• □ The FSN covers quarantine, retrieval, disposal, patient follow-up and forwarding requirements
• □ FSN delivery methods and record-keeping mechanisms are defined (4 categories of channels)
• □ FSCA and adverse event reporting are processed in parallel (neither replaces the other)
• □ The elements of the risk analysis are referenced in the background information

Regulatory information verified as of 29 October 2026. The regulations, guidance and effective dates described in this article are limited to the official sources listed in the legal basis section above as published on that date; where official documents have been updated, the most recently published version prevails.

• Local resources in South Africa: GRZAN assists manufacturers from the Chinese mainland and other markets with SAHPRA medical device establishment licence (MDEL) applications and product registration preparation, including authorised representative (AR) scheme design, ISO 13485 certification pathway planning and CAB selection, GMDN coding and classification determination, technical documentation, and the setup of vigilance and adverse event notification mechanisms.
• Service capabilities: product attribute determination and risk classification (Class A, B, C, D), establishment licence applications and renewals, reliance pathway argumentation, technical documentation and essential principles conformity argumentation, labelling and instructions for use localisation in English, and support for post-market vigilance and annual compliance submissions.
• Contact: info@grzanglobal.com; hito.lin@grzan.cn; website www.grzan.cn.